MedPath

The Clinical and Virology effects of NA inhibitor in influenza virus infections (age;over 4 years old, under 13 years old):an open-label,randomized study Part 2.

Not Applicable
Conditions
Childfood influenza infections
Registration Number
JPRN-UMIN000012670
Lead Sponsor
Hirotsu Clinic
Brief Summary

1st half of the study result (virus dynamics)were shown below: http://www.tandfonline.com/doi/pdf/10.1080/14787210.2018.1421945?needAccess=true 2nd half of the study result (antibody dynamics) has been submitted (under review)

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
160
Inclusion Criteria

Not provided

Exclusion Criteria

1)History of hypersensitivity caused by neuraminidase inhibitors. 2)Patients with (high risk factors) underlying disease that is estimated to affect the course of virus. 3)Patients were deemed inappropriate for the study participants.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
-Time to virus disappeared from the start of drug administration
Secondary Outcome Measures
NameTimeMethod
-Time to return to normal body temperature (under 37.5 degrees) -Time of flu symptoms to disappear -The amount of change per unit time of the virus titer to the last observation time and day 3 -The drug sensitivity change for each NA inhibitor -The time course and antibody titer -Rate of relapse
© Copyright 2025. All Rights Reserved by MedPath